drugset / Trial / NCT06645704
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration
NaSingle-groupOpen-labelTreatment
Summary
This study is being conducted to assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\]-EP262 in healthy male participants.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2024-12-10
- Completion
- 2024-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EP262 | Unknown | 25 mg | Oral |
Indications
No indication recorded.